The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years ...

After years of ongoing shortages due to their growing popularity, all doses of both Ozempic and Wegovy are now listed as ...

Semaglutide (Wegovy) reduced pain and improved physical function in patients with obesity and knee osteoarthritis, a ...

It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...

A large trial showed that semaglutide, sold as Ozempic for diabetes and as Wegovy for obesity, was better than any current ...

All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned ...

Wegovy reduced arthritic knee pain in study subjects with high BMI. Unknown: the exact mechanism or whether it would prevent knee replacement surgery.

With the cost of GLP-1s rising for employers, so-called compounded weight-loss drugs have emerged as a more cost-conscious ...

Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...

Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...

Eli Lilly and Company disappointed with missed earnings, lower guidance. Click here for my review of LLY Q3 earnings and a ...

The lowest dose of Novo Nordisk's weight-loss drug, Wegovy, was listed as available on the U.S. health regulator's website on Wednesday.